Leukemia Specialist Anthony Letai Named NCI Director

Anthony “Tony” Letai, a leukemia specialist at the Dana-Farber Cancer Institute and Harvard Medical School whose research on apoptosis and functional precision medicine helped pave the way for new cancer therapies and drug-selection strategies, has been tapped to lead the $7.2 billion National Cancer Institute.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0081
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Leukemia Specialist Anthony Letai Named NCI Director

Cancer Discovery
Acute Lymphoblastic Leukemia research
article

Leukemia Specialist Anthony Letai Named NCI Director

article en

Abstract

Anthony “Tony” Letai, a leukemia specialist at the Dana-Farber Cancer Institute and Harvard Medical School whose research on apoptosis and functional precision medicine helped pave the way for new cancer therapies and drug-selection strategies, has been tapped to lead the $7.2 billion National Cancer Institute.

Cancer Discovery
Openalex Percentile: Top 64%
Acute Lymphoblastic Leukemia research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Leukemia Specialist Anthony Letai Named NCI Director · Cancer Discovery (2025) | TGRS Research Map | TGRS